Figure 1.
Study overview. Drug resistance gene lists were generated for each subtype and treatment arm by performing differential expression between responders (RCB 0/I) and non-responders (RCB III). We then compared these drug resistance gene profiles to the Connectivity Map drug perturbation profiles for the MCF7 breast cancer cell line to identify drugs that can reverse these drug resistance genes. We tested our top hit, fulvestrant, in paclitaxel-resistant breast cancer cell lines.